5th Edition of World Nursing Research Conference 2026

Abstract

Clalit is the largest HMO in Israel, insuring more than 4.7 million individuals. It is also one of the largest integrated HMOs worldwide, second in size only to Kaiser Permanente in the US. C-Pi – Clalit Proactive and Preventative Interventions – is a flagship innovation platform developed internally by Clalit, by the joint collaborative efforts of the Community Care Division, the Information Systems and Digital Division, and Clalit Innovation. This innovative and unique platform combines big data, artificial intelligence and complex decision algorithms, all integrated to guide the primary care physicians at the point of care, providing them with evidence-based personalized insights. 

The vision of the C-Pi platform is structured that patients will receive proactive and preventive care, suitable to their current condition. These objectives are perused by crossing the most updated clinical guidelines with the patient's data in an attempt to identify care gaps and providing the primary care physician with actionable and handy knowledge to promote good clinical practice. In addition, the platform also integrates AI-based prediction models that help the physicians to identify high-risk patients for proactive interventions.

The former name of the project was POEMS - patient oriented evidence that matters -meaning that we aim to treat our patients in order to improve their morbidity and to reduce their mortality.

One of the clinical conditions for which the C-Pi platform provides clinical recommendations is diabetes mellitus, a major issue at the primary care clinic. In the nineties, there were only three main treatment options: Sulphonylureas, Metformin and Insulin. Fortunately, nowadays there are more than 60 medication options, each of them with different pros and cons. It is almost impossible for primary care physicians; responsible for providing evidence-based care, to remember all the different medication options, the inclusion and exclusion criteria used in their clinical trials, and the adverse effects that may be relevant for a specific patient. We thus used the current guidelines from the American Diabetes Association, integrated them with the options offered by the Israeli health services basket, in order to identify to right medication for the right patient, considering the patient's full medical history, including comorbidities such as atherosclerotic disease, heart failure, and chronic kidney disease. Each personalized treatment recommendation in the platform is provided along with detailed explanations and references form resources such as Dynamed (wwwdynamed.com).

In the same manner, expert committees create an ideal "clinical pathway" for each clinical condition, enabling patients to automatically “travel” through these pathways every single day and gather their personalized recommendations. This is already happening these days, with more than 1000 physicians, approximately one third of the primary care physician of Clalit, who are already using the C-Pi platform.

Another clinical condition that is addressed by the C-Pi platform is Hepatitis C. With the availability of new and very effective drugs to treat the Hepatitis C virus, the WHO is aiming to declare the world as free from hepatitis C by 2030. In March 2023, we added clinical recommendations relevant for this condition to C-Pi, in order to help with the global battel against Hepatitis C. We developed an AI algorithm that integrates the various patient characteristics to identify patients at high risk for Hepatitis C. These patients can then be proactively sent to an antibody blood test. Patients with positive antibody test results are sent to perform a PCR test, and those who are found to be active carriers will be presented to the physician at the C-Pi platform with treatment recommendations. The platform helps to guide the physicians to prescribe one of two relevant anti-viral treatments for hepatitis C, after checking the cross reaction between the patient's chronic medications and the potential treatments.

Obesity is a global epidemic and is a challenge for family doctors. The treatment is complex and varied.  The CPI innovation allows the doctor to view the patient's data (data extracted from the digital data in the medical record and the laboratory) the results are presented to the physician in a friendly and clear way and advice upon the best treatment according to the latest medical literature. A new drug that has passed all the regulatory processes and is approved for use will be updated in the system within a few days accompanied by clear instructions regarding the form of administration, with a reference to the medical literature

BY January 2025, we launched the C-Pi decision support module for the management of hyperlipidemia according to the latest European and Israeli guidelines, along with the C-Pi module for primary CVD prevention.

At the same time, and after technological challenges, we were able to create a link between the CPI and the EMR so that all CPI recommendations are automatically translated into laboratory tests/referrals/prescriptions without the doctor's active intervention.

In the second half of 2025, we will launch the chronic kidney disease version and integrate it within the C- PI module.

These modules will be supported by remote monitoring at the patient's own home, using blood pressure and glucose sensors that can broadcast the output directly to the patient record and into the C-Pi platform.

C-Pi is a ground breaking platform for clinicians, and as such we also put substantial efforts to continuously improve its usability and user experience – our routine quote is that for a busy physician 3 clicks for an answer are 2 clicks too many.